Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
Acknowledgment of Support
This activity is supported by educational grants from AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Integrated Oncology - a LabCorp Specialty Testing Group; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Community Practice Connections™: 15th Annual New York Lung Cancers Symposium®
Release Date: January 29, 2021
Expiration Date: January 29, 2022
Acknowledgement of Commercial Support
This activity is supported by educational grants from AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Integrated Oncology - a LabCorp Specialty Testing Group; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, and pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other health care professionals interested in the treatment of lung cancer may also participate.
Upon successful completion of this activity, you should be better prepared to:
•Evaluate emerging clinical evidence regarding the management of patients with nonmetastatic lung cancers
•Assess clinical data concerning single-agent and combination immunotherapeutic approaches to manage lung cancers
•Explain current and emerging therapeutic strategies over multiple lines of therapy for patients with oncogene-driven NSCLC subtypes
•Identify strategies for patients without actionable oncogenic drivers, including the role of chemotherapies and antiangiogenic strategies
•Describe approaches to mitigate and manage treatment-related toxicities in the care of patients with lung cancers
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AstraZeneca, Pfizer, Daiichi Sankyo
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Director, Cancer Center
Albert Einstein College of Medicine
Disclosures: Grant Research Support: National Cancer Institute; Consultant: GlaxoSmithKline, AstraZeneca, Clovis Oncology, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero; Shareholder: Stelexis
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant Research Support: Bristol Myers Squibb, Genentech; Consultant: Compensated consultant for Merck, Bristol Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; Shareholder: Has options from Shattuck Labs, Immunai, and Arcus; Other: Received travel support honoraria from AstraZeneca, Eli Lilly, and Bristol Myers Squibb.
Li Shu Fan Medical Foundation Endowed Professor
Department of Clinical Oncology
The Chinese University of Hong Kong
Sha Tin, Hong Kong
Disclosures: Grant Research Support: AstraZeneca, Bristol Myers Squibb, Clovis Oncology, G1 Therapeutics, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche, SFJ, Takeda, XCovery; Consultant: AbbVie, ACEA Therapeutics, Amgen AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cirina, CStone Pharmaceuticals, Daiichi Sankyo, Lilly, Fishawack Health, G1 Therapeutics, Gritstone Oncology, GeneDecode (uncompensated), Hengrui Therapeutics, Hutchison China MedTech, Ignyta, Incyte Corporation, IQVIA, Janssen, Loxo Oncology, Lunit, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, Novartis, OncoGenex Technologies, OrigiMed, Pfizer, Roche/Genentech, Sanofi-Aventis, R&D, SFJ Pharmaceuticals, Takeda Oncology, Vertex Pharmaceuticals, Virtus Medical, Yuhan Corporation; Shareholder: Sanomics, Hutchison China MediTech; Other: Board of Directors: AstraZeneca Hutchison China MediTech.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.